July 10, 2026
Genethon newsletter – 2026 Issue Number 2
Genethon, a unique non-profit gene therapy R&D organization founded by the French Muscular Dystrophy Association (AFM-Telethon), reported clinical trial updates for its best-in-class Duchenne muscular dystrophy (DMD) gene therapy and announced a unique collaboration with a US-based company to improve precision… (read more)
January 23, 2026
Genethon newsletter – 2026 Issue Number 1
PARIS, FRANCE (January 26, 2026) – Genethon, a unique non-profit gene therapy R&D organization founded by the French Muscular Dystrophy Association (AFM-Telethon), began the new year with an R&D licensing deal for its gene therapy approach to Pompe disease and continues pivotal clinical trials of its… (read more)
June 19, 2025
Genethon newsletter – 2025 Issue Number 1
PARIS, FRANCE (June 19, 2025) – Genethon, a unique non-profit gene therapy R&D organization founded by the French Muscular Dystrophy Association (AFM-Telethon), and its spin-off Atamyo Therapeutics made significant advances in their gene therapies for multiple rare diseases as highlighted in Genethon’s most recent… (read more)
December 18, 2024
Genethon newsletter – 2024 Issue Number 2
This last issue of 2024 year highlights several major clinical development and scientific milestones over the past several months for Genethon.
– Positive safety and efficacy results for the gene therapy GNT0004, set it apart from all other
May 30, 2024
Genethon newsletter – 2024 Issue Number 1
In this new issue, Frédéric Revah, Genethon’s CEO, reviews the results of gene therapy trial for Duchenne Muscular Dystrophy, sponsored by Genethon at Myology Congress and the advances of the
